X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - Pharma Industry News - 30/Sep 05:09

Monthly News Roundup - September 2025

FDA Approves Rhapsido (remibrutinib) as the First Bruton’s Tyrosine Kinase Inhibitor for Chronic Spontaneous Urticaria Novartis has announced FDA approval of Rhapsido as an oral treatment for adult patients with chronic spontaneous urticaria...

Articles similaires

Sorry! Image not available at this time

FDA Approves Rhapsido (remibrutinib) for the Treatment of Chronic Spontaneous Urticaria

drugs.com - 30/Sep 02:09

EAST HANOVER, N.J., Sept. 30, 2025 -- Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA)...

Sorry! Image not available at this time

FDA Approves KEYTRUDA QLEX: Game-Changing Subcutaneous Immunotherapy Formulation Transforms Oncology Treatment Paradigm

wn.com - 25/Sep 23:40

"FDA Approves KEYTRUDA QLEX" DelveInsight's market intelligence analysis reveals the transformative implications of the FDA's September 19, 2025...

Sorry! Image not available at this time

FDA Approves KEYTRUDA QLEX: Game-Changing Subcutaneous Immunotherapy Formulation Transforms Oncology Treatment Paradigm

wn.com - 25/Sep 23:40

"FDA Approves KEYTRUDA QLEX" DelveInsight's market intelligence analysis reveals the transformative implications of the FDA's September 19, 2025...

Sorry! Image not available at this time

SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU

zacks.com - 22/Sep 16:03

Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.

Sorry! Image not available at this time

FDA Approves Opzelura for Atopic Dermatitis in Children

drugs.com - 29/Sep 20:05

MONDAY, Sept. 29, 2025 -- The U.S. Food and Drug Administration has approved Opzelura cream 1.5 percent (ruxolitinib) for children ages 2 to 11 years...

Sorry! Image not available at this time

FDA Approves INLURIYO (Imlunestrant): A Game-Changer for ESR1-Mutated Metastatic Breast Cancer Treatment | DelveInsight’s Perspective

wn.com - 27/Sep 02:02

"FDA approved INLURIYO (imlunestrant) by Eli Lilly, on September 25, 2025" The pharmaceutical landscape for metastatic breast cancer treatment has...

Sorry! Image not available at this time

FDA Approves INLURIYO (Imlunestrant): A Game-Changer for ESR1-Mutated Metastatic Breast Cancer Treatment | DelveInsight’s Perspective

wn.com - 27/Sep 02:02

"FDA approved INLURIYO (imlunestrant) by Eli Lilly, on September 25, 2025" The pharmaceutical landscape for metastatic breast cancer treatment has...

Sorry! Image not available at this time

FDA Approves Qivigy (immune globulin intravenous, human-kthm) for Primary Humoral Immunodeficiency

drugs.com - 29/Sep 05:09

September 29, 2025 -- Kedrion Biopharma announced today that it has received FDA approval for Qivigy®, a new 10% Immunoglobulin for intravenous...

Sorry! Image not available at this time

RHAPSIDO (remibrutinib) tablet [Novartis Pharmaceuticals Corporation]

nlm.nih.gov - 03/Oct 04:00

Updated Date: Fri, 03 Oct 2025 00:00:00 EDT

Sorry! Image not available at this time

RHAPSIDO (remibrutinib) tablet [Novartis Pharmaceuticals Corporation]

nlm.nih.gov - 03/Oct 04:00

Updated Date: Fri, 03 Oct 2025 00:00:00 EDT

Les derniers communiqués